Christiana Stamoulis Sells 7,402 Shares of Hologic (NASDAQ:HOLX) Stock

Hologic, Inc. (NASDAQ:HOLX) Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the sale, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Hologic Stock Down 0.1%

Shares of NASDAQ HOLX opened at $73.89 on Friday. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The firm has a market cap of $16.43 billion, a price-to-earnings ratio of 30.66, a PEG ratio of 2.54 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The stock’s 50-day simple moving average is $67.53 and its 200-day simple moving average is $63.85.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the company earned $1.06 earnings per share. The company’s revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hologic

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its holdings in Hologic by 294.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,022,455 shares of the medical equipment provider’s stock worth $718,223,000 after buying an additional 8,227,318 shares in the last quarter. Invesco Ltd. grew its holdings in Hologic by 72.5% in the 2nd quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock worth $543,486,000 after buying an additional 3,505,828 shares in the last quarter. Victory Capital Management Inc. grew its holdings in Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after buying an additional 1,692,177 shares in the last quarter. Geode Capital Management LLC grew its holdings in Hologic by 1.7% in the 2nd quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after buying an additional 97,142 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Hologic by 1.6% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after buying an additional 69,878 shares in the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

HOLX has been the subject of several research analyst reports. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Hologic in a report on Wednesday, October 8th. Mizuho reissued a “neutral” rating and issued a $78.00 price objective (up from $70.00) on shares of Hologic in a report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday. Finally, BTIG Research reissued a “neutral” rating on shares of Hologic in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $79.23.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.